Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 1

1(16.7%)

Phase 3

1(16.7%)

6Total

N/A(4)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04653285Not ApplicableCompleted

Facilitating Motor Skill Learning in Parkinson's Disease III

Role: collaborator

NCT06580977Not ApplicableRecruiting

Exploring the Effects of Exercise on Memory and Cognition in Parkinson´s Disease

Role: collaborator

NCT02008721Phase 3Completed

Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach

Role: collaborator

NCT03886090Not ApplicableCompleted

Facilitating Motor Skill Learning in Parkinson's Disease II (FaST-PD II)

Role: collaborator

NCT03245216Not ApplicableCompleted

Facilitating Motor Skill Learning in Parkinson's Disease

Role: collaborator

NCT01856244Phase 1Completed

Stability and Balance in Locomotion Through Exercise

Role: collaborator

All 6 trials loaded